Women carrying benign breast lesions will be further divided and analyzed according to the Fitzgibbon's risk categories for invasive cancer risk (4). The Fitzgibbon's categories are:
1. No increased risk group including adenosis (other than sclerotic), duct ectasia fibroadenoma without complex features,
2. slightly increased risk group (1.5-20 times) which includes fibroadenoma with complex features, moderate or florid hyperplasia without atypia, sclerosing adenosis,
3. moderately increased risk group (4.0-5.0 times) includes atypical ductal and lobular hyperplasia and
4. markedly increased risk group (8.0-10.0 times) which includes ductal and lobular carcinomas In Situ Following the blood collection, detailed relevant clinical information of the patient will be registered in a case record form.
The data will include: age, country of birth, last menstrual period, lactation, number of children, age at first full-term pregnancy, age at onset of menopause, family history, medication, mammography findings, FNA results, tumor size, histological findings, biopsies, disease staging, and other relevant clinical information.
You may not be if
1. pregnancy,
2. experiencing menstruation, or
3. under hormonal or drug treatment.
Clareo Health | Using Test of SCM for Detection Breast Cancer
